Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502472 · ClinicalTrials.gov registry record · Phase 2
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
A Phase 2 study, sponsored by Inova Health Care Services.
- Terminated
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT04502472 is a Phase 2 study that was terminated before completion, run by Inova Health Care Services. The registered enrollment target is 109 participants.
The verdict
NCT04502472, a Phase 2 study, was terminated before completion, sponsored by Inova Health Care Services.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
Interventions
- BIOLOGICAL Convalescent plasma transfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2020-06-06 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04502472
The ClinicalTrials.gov registry entry for NCT04502472 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Convalescent plasma transfusion is the first listed.
NCT04502472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04502472 about?
NCT04502472 is a clinical study titled "Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma". The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
What is the current status of trial NCT04502472?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2020-06-06. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT04502472?
The interventions under investigation include: Convalescent plasma transfusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT04502472?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.